TOKYO – Astellas Pharma Inc. is streamlining its product lineup by selling off rights to 16 of its long-listed products to LTL Pharma Co. Ltd. in a deal worth ¥20.1 billion (US$177 million), a move that will enable Astellas to focus on newer and more profitable drugs.
HONG KONG – Having recently completed the acquisition of Belgium-based Ogeda SA, Astellas Pharma Inc. now has a potentially key drug candidate at its disposal as well as access to new programs to its drug development pipeline, all of which could provide boosts to its bottom line as it deals with an imminent patent cliff.
HONG KONG – Having recently completed the acquisition of Belgium-based Ogeda SA, Astellas Pharma Inc. now has a potentially key drug candidate at its disposal as well as access to new programs to its drug development pipeline, all of which could provide boosts to its bottom line as it deals with an imminent patent cliff. (See BioWorld Today, April 4, 2017.)
TOKYO – Peptidream Inc.'s stock, which had surged on Monday after inking a $1 billion-plus collaboration agreement, might have failed to keep the momentum going on Tuesday. But the news of a multitarget discovery and optimization collaboration agreement with U.S.-based Janssen Pharmaceuticals Inc. underscored the growth of the company, which now has 17 funded discovery collaboration deals. (See BioWorld Today, April 10, 2017.)
TOKYO – Peptidream Inc.'s stock, which had surged on Monday after inking a $1 billion-plus collaboration agreement, might have failed to keep the momentum going on Tuesday. But the news of a multitarget discovery and optimization collaboration agreement with U.S.-based Janssen Pharmaceuticals Inc. underscored the growth of the company, which now has 17 funded discovery collaboration deals. (See BioWorld Today, April 10, 2017.)
TOKYO – Despite the weakening yen and uncertainties in the drug pricing system, Japan's pharmaceutical market is still the most attractive in the Asia-Pacific region and only second to the U.S. globally, according to a recent report by BMI Research. The market's size and purchasing power as well as the strength of the regulatory environment makes the outlook of Japan's pharmaceutical industry highly promising.
TOKYO – Despite the weakening yen and uncertainties in the drug pricing system, Japan’s pharmaceutical market is still the most attractive in the Asia-Pacific region and only second to the U.S. globally, according to a recent report by BMI Research. The market’s size and purchasing power as well as the strength of the regulatory environment makes the outlook of Japan’s pharmaceutical industry highly promising.
TOKYO – Though Japan's drug sector will maintain a pro-innovation policy with the aim to maximize patient value, discussions between the country's Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical Research and Manufacturers of America (PHRMA) showed stark differences in opinions.
TOKYO – Though Japan's drug sector will maintain a pro-innovation policy with the aim to maximize patient value, discussions between the country's Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical Research and Manufacturers of America (PHRMA) showed stark differences in opinions.
